Incidence,mortality, and survival trends of soft tissue and bone sarcoma in Switzerland between 1996 and 2015 |
| |
| Institution: | 1. Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse, CH-3010 Bern, Switzerland;2. Department of Medical Oncology and Hematology, Cantonal Hospital St Gallen, Rorschacher Strasse 95, CH-9007 St Gallen, Switzerland;3. Department of Orthopedic Surgery, Inselspital, Bern University Hospital, Freiburgstrasse, CH-3010 Bern, Switzerland;4. University of Zurich and Institute of Pathology Enge, Hardturmstrasse 133, CH-8005 Zurich, Switzerland;5. Bone Tumour Reference Centre at the Institute of Pathology, University Hospital and University of Basel, Schoenbeinstrasse 40, CH-4031 Basel, Switzerland;6. Foundation National Institute for Cancer Epidemiology and Registration (NICER) c/o University of Zurich, Seilergraben 49, CH-8001 Zurich, Switzerland;7. Unit of Cancer Survivorship, Division of Clinical Epidemiology and Aging Research & Epidemiological Cancer Registry Baden-Württemberg, German Cancer Research Center (dkfz), Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany;1. Department of Experimental Medicine, Microbiology Section, University of Study of Campania “Luigi Vanvitelli”, Via De Crecchio, 7, 80138 Naples, Italy;2. Department of Woman, Child and of General and Specialized Surgery, University of Campania “Luigi Vanvitelli”, Largo Madonna delle Grazie, 1, 80138 Naples, Italy;1. Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital, The Capital Region, Nordre Fasanvej 57, 2000, Frederiksberg, Denmark;2. Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 9609 Medical Center Drive, Bethesda, MD, 20892-9778, USA;3. Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark;1. From the SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, United States;2. Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States;3. Department of Psychosocial and Community Health, The University of Washington, Seattle, WA, United States;4. Department of Pathology, The University of Colorado Denver School of Medicine, Denver, CO, United States;5. The Cancer Therapy and Research Center, Christus Santa Rosa Medical Center, San Antonio, TX, United States;1. Department of Medicine, College of Medicine, Hanyang University, Seoul, Republic of Korea;2. Department of Biomedical Informatics, College of Medicine, Yonsei University, Seoul, Republic of Korea;3. Center for Thyroid Cancer, Head and Neck Oncology Clinic, National Cancer Center, Goyang, Republic of Korea;4. Department of Cancer Control and Population Health, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Republic of Korea;5. Herings, The Institute of Advanced Clinical and Biomedical Research, Seoul, Republic of Korea;1. Department of Surgery, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic;2. Institute of Health Information and Statistics of the Czech Republic, Prague, Czech Republic;3. Institute of Biostatistics and Analyses, Medical Faculty, Masaryk University, Brno, Czech Republic;4. Department of Surgery, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic;5. Department of Anatomy, Second Faculty of Medicine, Charles University, Prague, Czech Republic;1. Cancer Research Centre, Cancer Council Queensland, Brisbane, Australia;2. School of Public Health and Social Work, Queensland University of Technology, Kelvin Grove, Brisbane QLD 4059, Australia;3. Cancer Research Division, Cancer Council New South Wales, Kings Cross, NSW 1340, Australia;4. Sydney School of Public Health, University of Sydney, NSW 2006, Australia;5. Menzies Health Institute Queensland, Griffith University, Gold Coast Campus, Parklands Drive, Southport QLD 4222, Australia;6. School of Mathematical Sciences, Queensland University of Technology, Gardens Point, Brisbane QLD 4000, Australia |
| |
| Abstract: | BackgroundResearch on soft-tissue sarcoma (STS) and bone sarcoma (BS) is increasingly in the focus of physicians and pharmaceutical companies. Expanding knowledge has improved the management of sarcoma and possibly survival. Here we provide the first population-based data on time trends of incidence, mortality, and survival of STS and BS diagnosed in Switzerland between 1996 and 2015.MethodsWe performed a retrospective registry study with data from the National Institute for Cancer Epidemiology and Registration (NICER) database in Switzerland between 1996 and 2015.ResultsWe identified 5384 STS patients and 940 BS patients. The three most common STS subtypes were undifferentiated/unclassified sarcoma (22.3%), liposarcoma (20.6%) and leiomyosarcoma (20.6%). Chondrosarcoma, osteosarcoma and Ewing sarcoma represented 40.4%, 27.0% and 15.2% of the BS group, respectively. The age-standardized incidence and mortality rates in 2011–2015 were 4.43 and 1.42 per 100,000 person-years for STS, and 0.91 and 0.42 for BS. Age-standardized incidence of STS in males was significantly higher during 1996–2000 than during 2001–2015; however, mortality rates did not change significantly over time. Five-year relative survival (RS) for STS improved significantly from 56.4% (95%CI 52.9–59.7 for 1996–2001) to 61.6% (95%CI 58.6–64.4 for 2011–2015) (p = 0.025). No improvement in 5-year RS for BS could be observed (RS 1996–2000: 69.6%, 95%CI 61.2–76.6; RS 2011–2015: 73.1%, 95%CI 66.6–78.6; p = 0.479).ConclusionIncidence rates of STS and BS have been stable since 2001. The longer RS in STS can be attributed to advances in sarcoma patient management. |
| |
| Keywords: | Sarcoma Incidence Mortality Survival Neoplasms Registries Switzerland |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
